U. Montpellier and F. , ICM -Montpellier Cancer Institute ICM -Montpellier Cancer Institute 7 Department of Medical Oncology, Paoli Calmette Institute 8 Department of Medical Oncology, Paul Papin Cancer Centre 9 Department of Medical Oncology, Department of Radiation Oncology, ICM -Montpellier Cancer Institute, pp.17-18

A. Bahl, S. Masson, A. Birtle, S. Chowdhury, and J. De-bono, Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents, Cancer Treatment Reviews, vol.40, issue.1, pp.170-177, 2014.
DOI : 10.1016/j.ctrv.2013.06.008

D. Berthold, G. Pond, F. Soban, R. De-wit, M. Eisenberger et al., Docetaxel Plus Prednisone or Mitoxantrone Plus Prednisone for Advanced Prostate Cancer: Updated Survival in the TAX 327 Study, Journal of Clinical Oncology, vol.26, issue.2, pp.242-247, 2008.
DOI : 10.1200/JCO.2007.12.4008

J. De-bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels et al., Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, The Lancet, vol.376, issue.9747, pp.1147-54, 2010.
DOI : 10.1016/S0140-6736(10)61389-X

G. Potter, S. Barrie, M. Jarman, and M. Rowlands, Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer, Journal of Medicinal Chemistry, vol.38, issue.13, pp.2463-71, 1995.
DOI : 10.1021/jm00013a022

G. Attard, A. Belldegrun, and J. De-bono, Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer, BJU International, vol.84, issue.9, pp.1241-1287, 2005.
DOI : 10.1016/0960-0760(94)90131-7

J. De-bono, C. Logothetis, A. Molina, K. Fizazi, S. North et al., Abiraterone and Increased Survival in Metastatic Prostate Cancer, New England Journal of Medicine, vol.364, issue.21, pp.1995-2005, 2011.
DOI : 10.1056/NEJMoa1014618

H. Scher, S. Halabi, I. Tannock, M. Morris, C. Sternberg et al., Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group, Journal of Clinical Oncology, vol.26, issue.7, pp.1148-59, 2008.
DOI : 10.1200/JCO.2007.12.4487

Z. Culig and F. Santer, Molecular aspects of androgenic signaling and possible targets for therapeutic intervention in prostate cancer, Steroids, vol.78, issue.9, pp.851-860, 2013.
DOI : 10.1016/j.steroids.2013.04.012

S. Badrising, V. Van-der-noort, I. Van-oort, H. Van-den-berg, M. Los et al., Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment, Cancer, vol.72, issue.15 suppl, pp.968-75, 2014.
DOI : 10.1002/cncr.28518

Y. Loriot, D. Bianchini, E. Ileana, S. Sandhu, A. Patrikidou et al., Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100), Annals of Oncology, vol.24, issue.7, pp.1807-1819, 2013.
DOI : 10.1093/annonc/mdt136

S. Cai, H. Wang, B. Bailey, A. Ernstberger, B. Juliar et al., Humanized Bone Marrow Mouse Model as a Preclinical Tool to Assess Therapy-Mediated Hematotoxicity, Clinical Cancer Research, vol.17, issue.8, pp.2195-206, 2011.
DOI : 10.1158/1078-0432.CCR-10-1959

B. Montgomery, T. Kheoh, A. Molina, J. Li, J. Bellmunt et al., Impact of Baseline Corticosteroids on Survival and Steroid Androgens in Metastatic Castration-resistant Prostate Cancer: Exploratory Analysis from COU-AA-301, European Urology, vol.67, issue.5
DOI : 10.1016/j.eururo.2014.06.042

C. Ryan, A. Molina, J. Li, T. Kheoh, E. Small et al., Serum Androgens As Prognostic Biomarkers in Castration-Resistant Prostate Cancer: Results From an Analysis of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.31, issue.22, pp.312791-312799, 2013.
DOI : 10.1200/JCO.2012.45.4595

S. Burgio, V. Conteduca, B. Rudnas, F. Carrozza, E. Campadelli et al., PSA Flare With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer, Clinical Genitourinary Cancer, vol.13, issue.1, pp.39-43, 2015.
DOI : 10.1016/j.clgc.2014.06.010

R. Leibowitz-amit, A. Templeton, A. Omlin, C. Pezaro, E. Atenafu et al., Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer, Annals of Oncology, vol.25, issue.3, pp.657-62, 2014.
DOI : 10.1093/annonc/mdt581

T. Beer, A. Armstrong, D. Rathkopf, Y. Loriot, C. Sternberg et al., Enzalutamide in Metastatic Prostate Cancer before Chemotherapy, New England Journal of Medicine, vol.371, issue.5, pp.424-457, 2014.
DOI : 10.1056/NEJMoa1405095

H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg et al., Increased survival with enzalutamide in prostate cancer after chemotherapy, N Engl J Med, vol.367, issue.13, pp.1187-97, 2012.

R. Van-soest, M. Van-royen, E. De-morree, J. Moll, W. Teubel et al., Cross-resistance between taxanes and new hormonal agents abiraterone and enzalutamide may affect drug sequence choices in metastatic castration-resistant prostate cancer, European Journal of Cancer, vol.49, issue.18, pp.3821-3851, 2013.
DOI : 10.1016/j.ejca.2013.09.026

J. Mezynski, C. Pezaro, D. Bianchini, A. Zivi, S. Sandhu et al., Antitumour activity of docetaxel following treatment with the CYP17A1 inhibitor abiraterone: clinical evidence for cross-resistance?, Annals of Oncology, vol.23, issue.11, pp.2943-2950, 2012.
DOI : 10.1093/annonc/mds119

M. Schweizer, X. Zhou, H. Wang, S. Bassi, M. Carducci et al., The Influence of Prior Abiraterone Treatment on the Clinical Activity of Docetaxel in Men with Metastatic Castration-resistant Prostate Cancer, European Urology, vol.66, issue.4, pp.646-52, 2014.
DOI : 10.1016/j.eururo.2014.01.018

C. Sternberg, D. Castellano, G. Daugaard, L. Géczi, S. Hotte et al., Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial, The Lancet Oncology, vol.15, issue.11, pp.1263-1271, 2014.
DOI : 10.1016/S1470-2045(14)70417-6